Hepatic fibrosis

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
4 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Erythropoietin analogue 1 substance
Phase III: 1 Phase II: 1 Phase I (Other): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Akero Therapeutics Inc. Commercial
    EFRUXIFERMIN
    2023-505141-48-00 5 countries 2024 n=244
    Recruiting

Phase II

1 trial
  • Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic
    IMP not specified
    2023-504100-28-00 1 country 2024 n=30
    Recruiting

Phase I (Other)

2 trials
  • Alentis Therapeutics AG Commercial
    IMP not specified
    2024-516455-40-00 2 countries 2023 n=37
    Ended
  • AstraZeneca AB Commercial
    IMP not specified
    2024-517605-91-00 1 country 2025 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alentis Therapeutics AG Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase I (Other) 0
Akero Therapeutics Inc. Commercial 1 Phase III 1
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau Academic 1 Phase II 1
New trials by year
2023
1
2024
2
2025
1
← All indication landscapes